Cellectis (CLLS) Downgraded to Hold at ValuEngine

Share on StockTwits

ValuEngine cut shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a research report report published on Friday morning.

CLLS has been the subject of a number of other research reports. BidaskClub lowered shares of Cellectis from a hold rating to a sell rating in a report on Friday, October 26th. Zacks Investment Research raised shares of Cellectis from a hold rating to a buy rating and set a $25.00 target price for the company in a report on Friday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Cellectis has a consensus rating of Hold and a consensus price target of $48.00.

CLLS opened at $21.72 on Friday. Cellectis has a 52 week low of $21.29 and a 52 week high of $38.85. The firm has a market cap of $915.32 million, a price-to-earnings ratio of -7.81 and a beta of 1.76.

Several hedge funds and other institutional investors have recently made changes to their positions in CLLS. FMR LLC boosted its position in shares of Cellectis by 18.0% during the second quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock worth $119,949,000 after purchasing an additional 647,164 shares in the last quarter. BlackRock Inc. boosted its position in shares of Cellectis by 259.7% during the second quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock worth $12,552,000 after purchasing an additional 320,340 shares in the last quarter. Nexthera Capital LP boosted its position in shares of Cellectis by 64.7% during the second quarter. Nexthera Capital LP now owns 548,212 shares of the biotechnology company’s stock worth $15,509,000 after purchasing an additional 215,458 shares in the last quarter. Laurion Capital Management LP bought a new position in shares of Cellectis during the second quarter worth $5,658,000. Finally, Macquarie Group Ltd. bought a new position in shares of Cellectis during the third quarter worth $5,390,000. 27.36% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Featured Story: Debt-To-Equity Ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply